Similar Search Results

The impact of the entry of biosimilars : evidence from Europe

Scott Morton, Fiona; Stern, Ariel D.; Stern, Scott - 2017

Persistent link: https://www.econbiz.de/10011708133

Public debate : the US food and drug administration and new drug approvals ; a safety vs. innovation paradox?

Hemphill, Thomas A. - In: Innovation: organization & management : IOM 15 (2013) 3, pp. 364-367

Persistent link: https://www.econbiz.de/10010226637

The economic consequences of US FDA new drug approvals : evidence from Taiwan pharmaceutical and biotech companies

Chen, Yong-Jie; Feng, Zhi-Yuan; Li, Yueh-Ping; Huang, … - In: Innovation: organization & management : IOM 23 (2021) 3, pp. 354-374

Persistent link: https://www.econbiz.de/10012649635

Evaluating the US pharmaceutical patent policy

Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2021

crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in … the US pharmaceutical industry. We estimate the effect of patent length and scope on generic entry prior to the expiration … of new drug patents using two quasi-experimental approaches: one based on changes in patent laws and another on the …

Persistent link: https://www.econbiz.de/10012802183

The NBER Orange Book Dataset : A User's Guide

Durvasula, Maya; Hemphill, C. Scott; Ouellette, Lisa … - National Bureau of Economic Research - 2022

This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....

Persistent link: https://www.econbiz.de/10013462677